Damora Therapeutics
DMRA
23 hedge funds and large institutions have $15.7M invested in Damora Therapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 4 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
1.83% less ownership
Funds ownership: 37.87% → 36.04% (-1.8%)
8% less funds holding
Funds holding: 25 → 23 (-2)
25% less capital invested
Capital invested by funds: $21M → $15.7M (-$5.3M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$589K |
| 2 |
Renaissance Technologies
New York
|
+$37.7K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$26.6K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$25.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$1.59M |
| 2 |
Two Sigma Investments
New York
|
-$147K |
| 3 |
Two Sigma Advisers
New York
|
-$71.2K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$18.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5K |
DMRA Hedge Fund Activity: Q2 2022 in Review
23 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q2 2022, worth a combined $15.7M — down 25% from $21M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DMRA and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 11 added.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $589K. The largest seller was Janus Henderson Group, exiting entirely with an estimated $1.59M sold.
- 23 institutional investors held Damora Therapeutics (DMRA) as of Q2 2022, down from 25 in Q1 2022.
- Funds reported $15.7M of Damora Therapeutics stock for Q2 2022, down 25% quarter-over-quarter.
- 2 funds opened new Damora Therapeutics positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Damora Therapeutics buyer in Q2 2022 was MAI Capital Management, an estimated $589K added.
- The largest Damora Therapeutics seller in Q2 2022 was Janus Henderson Group, an estimated $1.59M sold.
Based on aggregated 13F filings for Q2 2022.